Diasorin S.P.A.

Diasorin S.P.A. is an Italian-based medical diagnostics company with a U.S. subsidiary, Diasorin Inc., based in Stillwater, Minnesota, that specializes in advanced diagnostic testing equipment and solutions for federal healthcare agencies. The company manufactures chemiluminescence immunoassay analyzers and provides comprehensive laboratory diagnostic capabilities, including reagents, consumables, test kits, and technical support services. Through its federal contracting presence, Diasorin has established itself as a key supplier of specialized medical diagnostic solutions to multiple federal healthcare agencies, leveraging its proprietary LIAISON XL and LIAISON XS analyzer platforms for infectious disease testing and immunochemistry applications.

Diasorin's federal contract portfolio demonstrates substantial engagement across the Department of Veterans Affairs, Defense Health Agency, Centers for Disease Control and Prevention, Department of Health and Human Services, and the Indian Health Service. The company has received numerous prime contract awards valued from under $15,000 to over $4.6 million, with contract types including purchase orders, delivery orders, blanket purchase agreement calls, and definitive contracts. Diasorin's service offerings span the full spectrum of diagnostic support: equipment procurement (including LIAISON XL and LIAISON XS analyzers), reagent and consumable supplies for immunoassay testing, preventative maintenance and repair services, equipment leasing and rental arrangements, and comprehensive technical support. Notable large-value awards include a $4.61 million cost-per-kit agreement with the Defense Health Agency for chemiluminescence immunoassay reagents at Brooke Army Medical Center, a $1.997 million Defense Health Agency contract for reagents and analyzers, and a $1.136 million Veterans Integrated Service Network 22 contract for immunoassay reagents. The company has also supplied HIV testing kits and reagents, tuberculosis testing equipment and services, and specialized diagnostic solutions for conditions including COVID-19, cytomegalovirus, Epstein-Barr virus, and other critical infectious diseases. All of Diasorin's federal awards have been made without set-aside designations, reflecting the company's competitive positioning and specialized technical capabilities in the federal healthcare diagnostics market. The company has consistently served as a prime contractor without identified subcontractors on the awards reviewed.

Diasorin S.P.A. maintains multiple significant Indefinite Delivery Vehicles across federal agencies that enable efficient procurement of its diagnostic solutions. The company holds a $10 million Federal Supply Schedule contract with the Department of Veterans Affairs for diagnostic equipment, reagents, and services; a $2.8 million General Services Administration Multiple Award Schedule contract; and various single-award Indefinite Delivery Contracts with specific VA Veterans Integrated Service Networks valued between $750,000 and $2 million. These IDVs operate under parent vehicles including the Critical Analyzers, Laboratory Federal Supply Schedule (FSS-66-III), which allows multiple federal healthcare agencies to procure Diasorin's LIAISON analyzer systems and associated consumables through streamlined procedures. Task orders against these vehicles have been issued by Veterans Integrated Service Networks 4, 5, 8, 9, 10, 15, 17, 20, 21, 22, and 23, as well as by the Defense Health Agency, demonstrating broad utilization across the VA healthcare system and Department of Defense. The IDV structure enables federal agencies to access Diasorin's specialized diagnostic testing capabilities at pre-negotiated pricing, supporting everything from equipment procurement to cost-per-test arrangements and comprehensive maintenance programs. These indefinite delivery vehicles have generated consistent task order activity, with individual delivery orders and call orders typically ranging from $12,000 to over $600,000, providing federal healthcare facilities with flexible access to critical diagnostic equipment and reagent supplies essential for infectious disease diagnostics and laboratory operations across the federal healthcare network.